Affinia Therapeutics

Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.

Affinia Therapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $5.4B in funding across 32 round(s). With a team of 51-100 employees, Affinia Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Affinia Therapeutics, raised $110.0M. Discover more about their projects, partnerships, and impact on our platform.